Clinical Trial Detail

NCT ID NCT02983045
Title A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Nektar Therapeutics
Indications

renal cell carcinoma

lung non-small cell carcinoma

melanoma

Therapies

Nivolumab + NKTR-214

Age Groups: adult senior

No variant requirements are available.